Safety and metabolic outcomes of resveratrol supplementation in older adults: Results of a twelve-week, placebo-controlled pilot study
Open accessAbstract
Resveratrol has been found to have potent antioxidant, anti-inflammatory, and anticarcinogenic effects. The safety and efficacy of resveratrol supplementation in older adults are currently unknown. We conducted a double-blind, randomized, placebo-controlled trial to examine the safety and metabolic outcomes in 32 overweight, older adults (mean age, 73±7years). Participants were randomized into one of three treatment groups: (1) placebo, (2) moderate dose resveratrol (300mg/day), and (3) high dose resveratrol (1000mg/day). Both resveratrol and placebo were orally ingested in capsule form twice daily for 90days. Blood chemistry values remained within the normal range, and there were no significant differences in the number of participants reporting adverse events across conditions. Compared to placebo, glucose levels were significantly lower at post-treatment among participants randomized to both resveratrol conditions, with and without adjustment for the corresponding baseline values (ps<0.05). Glucose values of participants in the treatment groups, however, were not significantly different from baseline levels. These findings suggest that short-term resveratrol supplementation at doses of 300mg/day and 1000mg/day does not adversely affect blood chemistries and is well tolerated in overweight, older individuals. These findings support the study of resveratrol for improving cardio-metabolic health in older adults in larger clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the 2014 study, a decrease in hemoglobin levels and mean corpuscular volume was observed in patients receiving 300 mg/day resveratrol, whereas patients given the highest dose (1000 mg/day) had an increase in alkaline phosphatase and aspartate aminotransferase levels.
“However, a decrease in hemoglobin levels and mean corpuscular volume was observed in the group of patients receiving 300 per day of resveratrol, whereas the patients given the highest dose had an increase in alkaline phosphatase and aspartate aminotransferase levels [40].”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [40]
In the 2014 study, after 90 days, fasting glucose and bilirubin levels were significantly lower in patients treated with resveratrol than in those receiving placebo, but not compared to values at study enrollment.
“After 90 days of treatment, fasting glucose and bilirubin levels were significantly lower in patients treated with resveratrol than in those receiving placebo, but not compared to the values at study enrollment.”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796 · see citing works
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320 · see citing works
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-074903-4.x5000-6 · Cited by 1,073 · see citing works
Bioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051 · see citing works
Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2364 · Cited by 691 · see citing works
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.06.003 · Cited by 475 · see citing works
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszár, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 433 · see citing works
Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C. C., Kunz, I., Fanelli, F. R., Patterson, B. W., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.015 · Cited by 381 · see citing works
Novotný, L., & Vı́tek, L. (2003) · Experimental Biology and Medicine · doi:10.1177/15353702-0322805-29 · Cited by 347 · see citing works
Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study
Chow, H. ‐. S., Garland, L. L., Hsu, C., Vining, D. R., Chew, W. M., Miller, J. A., Perloff, M., Crowell, J. A., & Alberts, D. S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0155 · Cited by 333 · see citing works
The Daily Oral Administration of High Doses of trans-Resveratrol to Rats for 28 Days Is Not Harmful
Juan, M. E., Vinardell, M. P., & Planas, J. M. (2002) · Journal of Nutrition · doi:10.1093/jn/132.2.257 · Cited by 293 · see citing works
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Chachay, V., Macdonald, G. A., Martin, J. H., Whitehead, J. P., O'Moore‐Sullivan, T. M., Lee, P., Franklin, M. E., Klein, K., Taylor, P. J., Ferguson, M. L., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.024 · Cited by 291 · see citing works
Cardiovascular effects and molecular targets of resveratrol
Li, H., Xia, N., & Förstermann, U. (2012) · Nitric Oxide · doi:10.1016/j.niox.2011.12.006 · Cited by 288 · see citing works
Pilot study of resveratrol in older adults with impaired glucose tolerance
Crandall, J. P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H. W., & Barzilai, N. (2012) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glr235 · Cited by 281 · see citing works
Tomé‐Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M. J., García‐Almagro, F. J., Ruiz‐Ros, J. A., García‐Conesa, M., Tomás-Barberán, F. A., & Espı́n, J. C. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.030 · Cited by 260 · see citing works
Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients
Movahed, A., Nabipour, I., Louis, X. L., Thandapilly, S. J., Yu, L., Kalantarhormozi, M., Rekabpour, S. J., & Netticadan, T. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/851267 · Cited by 258 · see citing works
Tomé‐Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M. J., García‐Almagro, F. J., Ruiz‐Ros, J. A., Tomás-Barberán, F. A., García‐Conesa, M., & Espı́n, J. C. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6427-8 · Cited by 241 · see citing works
Virgili, M., & Contestabile, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00820-x · Cited by 234 · see citing works
The journey of resveratrol from yeast to human
Timmers, S., Auwerx, J. H., & Schrauwen, P. (2012) · Aging · doi:10.18632/aging.100445 · Cited by 174 · see citing works
Militaru, C., Donoiu, I., Crăciun-Mirescu, A., Scorei, I. D., Bulearca, A. M., & Scorei, I. R. (2012) · Nutrition · doi:10.1016/j.nut.2012.07.006 · Cited by 161 · see citing works
Hematology and Clinical Biochemistry
Ringler, D. H., & Dabich, L. (1979) · Elsevier eBooks · doi:10.1016/b978-0-12-074901-0.50012-5 · Cited by 154 · see citing works
Gélinas, S., & Martinoli, M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10315 · Cited by 138 · see citing works
The Association of Serum Bilirubin Levels on the Outcomes of Severe Sepsis
Patel, J. J., Taneja, A., Niccum, D. E., Kumar, G., Jacobs, E. R., & Nanchal, R. S. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613488739 · Cited by 123 · see citing works
Resveratrol and liver disease: from bench to bedside and community
Bishayee, A., Darvesh, A. S., Politis, T., & McGory, R. W. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02295.x · Cited by 104 · see citing works
Extreme Bilirubin Levels as a Causal Risk Factor for Symptomatic Gallstone Disease
Stender, S., Frikke‐Schmidt, R., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6465 · Cited by 53 · see citing works
Associations between serum total bilirubin levels and functional dependence in the elderly
Kao, T., Chou, C. H., Wang, C., Chou, C.-W., Hu, J., & Chen, W. L. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02620.x · Cited by 28 · see citing works
Poulsen, M. M., Ørnstrup, M. J., Harsløf, T., et al. (2013) · Journal of Functional Foods · doi:10.1016/j.jff.2013.10.019 · Cited by 28 · see citing works
Serum bilirubin as a prognostic marker in patients with acute decompensated heart failure
Chintanaboina, J., Haner, M. S., Sethi, A., et al. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.3.300 · Cited by 25 · see citing works
Nocera, J. R., Buford, T. W., Manini, T. M., Naugle, K. M., Leeuwenburgh, C., Pahor, M., Perri, M. G., & Anton, S. D. (2011) · Journal of Aging Research · doi:10.4061/2011/392510 · Cited by 15 · see citing works
Self-citationPoulsen, M. M., Ørnstrup, M. J., Harsløf, T., et al. (2013) · Bone Abstracts · doi:10.1530/boneabs.1.pp110
Flagged first, then by citations
Cited by
Sorted by citations
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523 · see citing works
Nutritional psychiatry: Towards improving mental health by what you eat
Adan, R. A. H., van der Beek, E. M., Buitelaar, J. K., Cryan, J. F., Hebebrand, J., Higgs, S., Schellekens, H., & Dickson, S. L. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.10.011 · Cited by 454 · see citing works
Resveratrol, human health and winemaking perspectives
Pastor, R. F., Restani, P., Di Lorenzo, C., Orgiu, F., Teissedre, P.-L., Stockley, C., Ruf, J. C., Quini, C. I., Garcìa Tejedor, N., Gargantini, R., et al. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1400517 · Cited by 123 · see citing works
The Role of Resveratrol Administration in Human Obesity
Mongioì, L. M., La Vignera, S., Cannarella, R., Cimino, L., Compagnone, M., Condorelli, R. A., & Calogero, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094362 · Cited by 71 · see citing works
- Authors
- Anton, S. D., Embry, C., Marsiske, M., Lu, X., Doss, H., Leeuwenburgh, C., & Manini, T. M.
- Affiliations
- University of Florida Health (US)
- University of Florida (US)
- Corresponding author
- Anton, Stephen D.
- Manini, Todd M.
- Venue
- Experimental Gerontology
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 57
- Pages
- 181-187
- ISSN
- 0531-5565 (ISSN-L)
- PMC
- PMC4149922
- OpenAlex
- W2077214005
- Cited by
- 95
- References
- 31
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 7 · 2021: 9 · 2020: 6 · 2019: 10 · 2018: 9 · 2017: 10 · 2016: 5 · 2015: 3 · 2014: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Experimental Gerontology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Florida's McKnight Brain Institute
- Claude D. Pepper Older Americans Independence Center (NIH/NIA P30AG028740)
- Clinical and Translational Science Institute (NIH/NCRR UL1TR000064)
- Early Career Investigator (K23 AT004251-01A2)
- American Heart Association (09CRP2390173)
- Thomas H. Maren Foundation
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- resveratrol, dietary supplementation, older adults, overweight, glucose concentration, serum biochemistry, safety, adverse events, cardiometabolic health, dose comparison
- MeSH terms
- Resveratrol, Aged, Anthropometry, Anti-Inflammatory Agents, Non-Steroidal, Blood Glucose, Blood Pressure, Female, Humans, Male, Pilot Projects, Stilbenes, Dietary Supplements, Overweight, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
